SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) ROCE %: 7.07% (As of Mar. 2026)


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
64 GF Score
Price $0.47
GF Value $0.57
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co ROCE %?

Shenzhen Hepalink Pharmaceutical Group Co SHEZF 64 ROCE % is 7.07% as of Mar. 2026. GuruFocus rates SHEZF with a GF Score™ of 64/100 and a GF Value™ of $0.57. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shenzhen Hepalink Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.07%.

Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shenzhen Hepalink Pharmaceutical Group Co ROCE % Related Terms

Shenzhen Hepalink Pharmaceutical Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co ROCE % Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.89 6.89 -4.73 6.16 3.66

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.89 9.70 5.29 -6.94 7.07
SHEZF
64GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co ROCE % Calculation

Shenzhen Hepalink Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=67.253/( ( (2382.123 - 508.088) + (2361.393 - 561.304) )/ 2 )
=67.253/( (1874.035+1800.089)/ 2 )
=67.253/1837.062
=3.66 %

Shenzhen Hepalink Pharmaceutical Group Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=128.108/( ( (2361.393 - 561.304) + (2468.43 - 646.346) )/ 2 )
=128.108/( ( 1800.089 + 1822.084 )/ 2 )
=128.108/1811.0865
=7.07 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.07% mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a ROCE % of 7.07% as of Mar. 2026.
Is Shenzhen Hepalink Pharmaceutical Group Co's ROCE % too high?
Shenzhen Hepalink Pharmaceutical Group Co's current ROCE % is 7.07%. The Drug Manufacturers industry median ROCE % is 7.00. Shenzhen Hepalink Pharmaceutical Group Co's value of 7.07% is 1.1% above this industry median. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's ROCE % compare to ZTS?
Shenzhen Hepalink Pharmaceutical Group Co's ROCE % of 7.07% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Shenzhen Hepalink Pharmaceutical Group Co's value of 7.07% is 1.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current ROCE % of 7.07% is 1.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current ROCE % is 7.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current ROCE % of 7.07%. The stock's GF Value™ is $0.57, compared to a current price of $0.47 — trading 17.6% below its estimated fair value. The current ROCE % is 7.07% and 1.1% above the Drug Manufacturers industry median of 7.00. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current ROCE % is 7.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 17.6% below its estimated GF Value™ of $0.57.

Key valuation signals for SHEZF:

  • ROCE %: 7.07%
  • GF Value™: $0.57 vs. price of $0.47 (17.6% below fair value)
  • GF Score™: 64/100 with 7 warning signs
  • Industry Position: 1.1% above the Drug Manufacturers median

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
64GF Score

Get the complete analysis for SHEZF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.57
GF Value